Grant: Fellowship - PA: CIHR/Rx&D - CAMO Research Program
University of Toronto
$55,000.00
Evaluating the anti-tumor activity of a dual IGF-1R and IR inhibitor (OSI-906) in genomically characterized human breast cancer (BC) xenograft models.
EF 2010-11
Résumé
Breast cancer is the most common cancer diagnosed in Canadian women (excluding non-melanoma skin cancer). Despite advances in early detection and treatment, breast cancer remains the second-leading cause of cancer death in Canadian women. There is an urgent need to develop improved therapies for women with advanced breast cancer. OSI-906 is a promising new drug that blocks two critical pathways involved in breast cancer growth and resistance to existing treatments, the Insulin Growth Factor-1 Receptor (IGF-1R) and the Insulin Receptor (IR). The aim of this project is to test OSI-906, either alone or in combination with other promising new drugs, in mouse models implanted with samples of breast tumors donated by women with advanced breast cancer. This will provide a better understanding of which types of breast cancer are likely to benefit from treatment with OSI-906 either alone or in combination with other promising new drugs that can be tested in future clinical trials involving patients with breast cancer.
Programme
Fellowship - PA: CIHR/Rx&D - CAMO Research Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
215847
Name
Sahebjam Solmaz
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association of Medical Oncologists (Ottawa)
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
Evaluating the anti-tumor activity of a dual IGF-1R and IR inhibitor (OSI-906) in genomically characterized human breast cancer (BC) xenograft models.
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$55,000
Cihrequipment2
$0
Programname2
Fellowship - PA: CIHR/Rx&D - CAMO Research Program
Keyworddelim
Breast Cancer; Dual Inhibitor Of Igf-1r And Ir; Patient-Derived Human Tumor Xenografts; Predictive Markers; Targeted Agents; Targeted Sequencing
Abstract
Breast cancer is the most common cancer diagnosed in Canadian women (excluding non-melanoma skin cancer). Despite advances in early detection and treatment, breast cancer remains the second-leading cause of cancer death in Canadian women. There is an urgent need to develop improved therapies for women with advanced breast cancer. OSI-906 is a promising new drug that blocks two critical pathways involved in breast cancer growth and resistance to existing treatments, the Insulin Growth Factor-1 Receptor (IGF-1R) and the Insulin Receptor (IR). The aim of this project is to test OSI-906, either alone or in combination with other promising new drugs, in mouse models implanted with samples of breast tumors donated by women with advanced breast cancer. This will provide a better understanding of which types of breast cancer are likely to benefit from treatment with OSI-906 either alone or in combination with other promising new drugs that can be tested in future clinical trials involving patients with breast cancer.
Competitiondate
201010
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Sahebjam, Solmaz
Approvedterm
2 ans 0 mois
Cihrcontribution2
Patient Oriented Research~ $55,000~ $0~